Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does GOSERELIN Cause Malignant neoplasm progression? 935 Reports in FDA Database

Prostate Health & Male Vitality — Naturally

ProstaVive: better flow, better sleep, better energy. 180-day guarantee.

Learn More

According to the FDA Adverse Event Reporting System (FAERS), 935 reports of Malignant neoplasm progression have been filed in association with GOSERELIN (ZOLADEX). This represents 14.7% of all adverse event reports for GOSERELIN.

935
Reports of Malignant neoplasm progression with GOSERELIN
14.7%
of all GOSERELIN reports
85
Deaths
114
Hospitalizations

How Dangerous Is Malignant neoplasm progression From GOSERELIN?

Of the 935 reports, 85 (9.1%) resulted in death, 114 (12.2%) required hospitalization, and 12 (1.3%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for GOSERELIN. However, 935 reports have been filed with the FAERS database.

What Other Side Effects Does GOSERELIN Cause?

Death (1,293) Metastases to bone (397) Neutropenia (339) Fatigue (309) Off label use (272) Metastases to liver (264) Hot flush (263) Asthenia (213) Arthralgia (190) Drug ineffective (189)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which GOSERELIN Alternatives Have Lower Malignant neoplasm progression Risk?

GOSERELIN vs GRAMICIDIN GOSERELIN vs GRAMICIDIN\NEOMYCIN\POLYMYXIN B GOSERELIN vs GRAMICIDIN\POLYMYXIN B GOSERELIN vs GRANISETRON GOSERELIN vs GRANULOCYTE COLONY-STIMULATING FACTOR NOS

Related Pages

GOSERELIN Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression GOSERELIN Demographics